Hagop M. Kantarjian, MD | Authors

March 10, 2022

Jorge E. Cortes, MD and Hagop Kantarjian, MD share a summary on ponatinib in CML and ALL and exploration of potential future studies.

March 03, 2022

Experts review future implications such as using ponatinib in earlier lines of therapy and in patients with Ph-positive ALL.

March 03, 2022

Jorge E. Cortes, MD and Hagop Kantarjian, MD debate optimal dosing and discuss how they use ponatinib in patients with CML.

February 24, 2022

Hagop Kantarjian, MD responds to a review of dosing options in patients with CML treated with ponatinib.

February 24, 2022

Dr. Cortes reviews ponatinib dosing strategies based on patient profiles and mutational status.

February 17, 2022

Hematologic oncologists summarize the dose ranging study of ponatinib in patients with CML and discuss clinical implications of this work.

February 17, 2022

Jorge E. Cortes, MD, presents data from a dose ranging study of ponatinib in patients with chronic-phase chronic myeloid leukemia.

June 01, 2016

Myelodysplastic syndromes (MDS) are a group of hematologic malignancies of the pluripotent hematopoietic stem cells. These disorders are characterized by ineffective hematopoiesis, including abnormalities in proliferation, differentiation, and apoptosis.

June 01, 2016

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder resulting from the neoplastic transformation of the primitive hematopoietic stem cell.

September 12, 2012

In this review, we will discuss the management of ALL in the adult population, in the context of the recently published guidelines from the NCCN. We will focus in particular on the strides being made in salvage and targeted approaches.